Agenus Inc. , a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies; and partnership with Phyton Biotech. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers https://investor.agenusbio.com/2019-11-11-Agenus-receives-10M-from-UroGen-Pharma-for-rights-to-Zalifrelimab-CTLA-4-for-intravesical-treatment-of-urinary-tract-cancers#.XcliPbz8L9E.twitter

Agenus Provides Corporate Update with Third Quarter 2019 Financial Results - Nov 4, 2019 https://investor.agenusbio.com/2019-11-04-Agenus-Provides-Corporate-Update-with-Third-Quarter-2019-Financial-Results#.XcAdXjTdTI8.twitter

$AGEN COO Dr. Jennifer Buell is featured in @PharmExec. Read insights into how @agenusbio pipeline, including nextgen CTLA-4 and bispecifics is designed to bring high impact products to patients @jbuell01 http://www.pharmexec.com/next-generation-focus-immuno-oncology #biotech #Cancer

$AGEN Innovation: GSK's Shingrix vaccine containing @Agenus_Bio #QS-21 crosses $1Bn in sales. https://www.reuters.com/article/us-gsk-results/gsk-raises-profit-forecast-after-shingles-vaccine-sales-boost-idUSKBN1X91EK?utm_source=applenews #VaccinesSaveLives

$AGEN satisfies contractual obligation & files registration statement to register shares previously sold to GILD (JAN2019). No new shares sold.

$AGEN Dr. Paisley Myers is featured in @touchONCOLOGY with insights into our proprietary PTT neoantigen platform & approach to novel cancer therapies with antibodies, vaccines, cell therapies #featured #oncology https://touchoncology.com/wp-content/uploads/sites/2/2019/10/Myers_Epub.pdf

LATEST NEWSLETTER: #ESMO19 CTLA-4 & PD-1 inhibitors demonstrate remarkable efficacy and durability; $AGEN CTLA-4 & PD-1 advance for planned BLA filing 2020 #Immunotherapy https://agenusbio.com/wp-content/uploads/2019/10/AGENUS_News_Vol2_Issue18.pdf

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

Agenus Inc.

3 Forbes Road
Lexington, MA 02421

+1 (781) 674-4400

www.agenusbio.com

November 2019
S M T W T F S
« Oct    
 12
3456789
10111213141516
17181920212223
24252627282930

©2019 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account